Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: Preliminary results and review of the literature

Annals of Oncology

Volumn 17, Issue SUPPL. 5, 2006, Pages

  Pastorelli, D ^a   Cartei, G ^a   Zustovich, F ^a   Marchese, F ^a   Artioli, G ^a   Zovato, S ^a   Binato, S ^a   Ceravolo, R ^a   Cingarlini, S ^a   Salmaso, F ^a   Mattiazzi, M ^a   Sanavio, C ^d   Farinati, F ^c   Zanus, G ^b   Cillo, U ^b  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b OU Epatobiliary Surgery and Hepatic Transplantation   (Italy)

^c Department of Gastroenterologic and Surgery Sciences PG Cevese ^*  (Italy)

^d General Hospital   (Italy)

Author keywords

Biliary tract cancers; Chemotherapy; Hepatocellular carcinoma

Indexed keywords

5 ETHYNYLURACIL; ANTHRACYCLINE; BLEOMYCIN; CAPECITABINE; CISPLATIN; CLOFAZIMINE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HYDROXYUREA; IDARUBICIN; IFOSFAMIDE; MITOMYCIN C; MITOXANTRONE; NOLATREXED; OXALIPLATIN; PACLITAXEL; SEMUSTINE; TOPOTECAN; VINBLASTINE; VITAMIN K GROUP; ZINOSTATIN;

ADVANCED CANCER; BILE DUCT CANCER; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LIVER CELL CARCINOMA; MONOTHERAPY; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STOMATITIS; THROMBOCYTOPENIA;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; CARCINOMA, HEPATOCELLULAR; DEOXYCYTIDINE; DISEASE PROGRESSION; DOXORUBICIN; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 33745597366     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj972     Document Type: Review

References (25)

1. Scheithauer W. Review of Gemcitabine in biliary tract carcinoma. Semin Oncol 2002; 29 (suppl 20): 40-45.
2. Castro MP. Efficacy of Gemcitabine in the treatment of patients with gallbladder carcinoma: A case report. Cancer 1998; 82: 639-641.
3. Kornek GV, Schuell B, Laengle F et al. Mitomycin C in combination with capecitabine or biweekly high-dose Gemcitabine in patients with advanced biliary tract cancer: A randomised phase II trial. Ann Oncol 2004; 15: 478-483.
4. Thongprasert S, Napapan S, Charoentum C et al. Phase II study of Gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 2005; 16: 279-281.
5. Vauthey JN, Klimstra D, Franceschi D et al. Hepatic resection for hepatocellular carcinoma. Am J Surg 1995; 169: 28.
6. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med 1996; 334(11): 693.
7. Jiang W, Lu Z., He Y., Diasio RB. Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: Implication in 5-fluorouracil -based chemotherapy. Clin. Cancer Res 1997; 3(3): 395.
8. Chevinesse X, Franco D, Brechot C. MDR I (multiple resistance) gene expression in human primary liver cancer and cirrhosis. J. Hepatol 1993; 18: 68.
9. Andrè T, Tournigand C, Rosmorduc O et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: A GERCOR study. Ann Oncol 2004; 15: 1339-1343.
10. Hsu C, Shen Y-C, Yang et al. Weekly Gemcitabine plus 24-h infusion of high-dose 5-fliorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract. Br J Cancer 2004; 90 (9): 1715-9.
11. Tsavaris N, Kosmas C, Gouveris P et al. Weekly Gemcitabine for the treatment of biliary tract and gallbladder cancer. Investigational New Drugs 2004; 22: 193-198.
12. Knox JJ, Hedley D, Oza A et al. Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: A review of the Princess Margaret Hospital experience. Ann Oncol 2004; 15: 770-774.
13. Lai CI, Wu PC, Chan GC et al. Doxorubicin vs. no antitumor therapy in an operable hepatocellular carcinoma: A prospective randomized trial. Cancer, 1988; 62: 479.
14. Simonetti RG, Liberati A, Angiolini C et al. Treatment of hepatocellular carcinoma: A systemic review of randomized controlled trials. Ann Oncol 1997; 8: 117.
15. Yang T, Wang C, Hsieh R et al. A 2-stage phase II study of Gemcitabine and Doxorubicin in patients with advanced hepatocellular carcinoma. Proc ASCO 2001; 20: Abstr 670.
16. Yang S, Lin YC, Chen JS, Wang HM, Wang CH. Phase II study of Gemcitabine in patients with advanced hepatocellular carcinoma. American Cancer Society 2000.
17. Ulrich-Pur H, Komek GV, Fiebiger W, Schuil B, Raderer M, Scheithauer W. Treatment of advanced hepatocellular carcinoma with biweekly high-dose Gemcitabine. Oncology 2001; 60: 313-315.
18. Ruff P, Moodley S, Repoport B et al. Long term follow up of pegylated Liposomal Doxorubicin (Caelyx): A well tolerated and effective agent in advanced hepatocellular carcinoma (HCC). Proc ASCO 2001; 20: Abstr 667.
19. Muggia F, Hamilton A. Phase III data on Caelyx in ovarian cancer. Eur J Cancer 2001; 37: S15-S18.
20. Martin FJ. Pegylated liposomal Doxorubicin: Scientific rationale and preclinical pharmacology. Oncology 1997; 11: 11-20 (Suppl 11).
21. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal Doxorubicin. Rationale for use in solid tumors. Drugs 1997; 54 (Suppl 4): 15-21.
22. Cartei G, Zustovich F, Murrone A et al. A phase I-II study of liposomal Doxorubicin (LD) in the treatment of hepatocellular carcinoma (HCC) not suitable for loco-regional therapy. Journal of Clinical Oncology 2005; 23 (Suppl 16).
23. Pastorelli D, Cartei G, Zustovich F et al. A phase II study of Gemcitabine (G) in combination with Liposomal Doxorubicin (LD) for hepatocellular carcinoma (HCC) otherwise untreatable. Ann Oncoll 2005; 16 (Suppl 4).
24. Alberts SR, Al-Khatib H, Mahoney MR et al. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: A North Central Cancer Treatment Group phase II trial. Cancer 2005; 103: 111-8.
25. von Delius S, Lersch C, Schulte-Frohlinde E, Mayr M, Schmid RM, Eckel F. Phase II trial of weekly 24-hour infusion of Gemcitabine in patients with advanced gallbladder and biliary tract carcinoma. BMC Cancer 2005; 5: 61.